Clinical Trial Update: Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of iparomlimab and tuvonralimab with GemOX chemotherapy and lenvatinib as conversion therapy for initially pot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Gallbladder Cancer
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Lenvatinib (lenvatinib)
• OXALIPLATIN (Oxaliplatin)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: BTC | Phase 2 | Status: NOT_YET_RECRUITING